Table 7.
Baseline Characteristics of US Adults Taking Antihypertensive Medication Who Meet BP Treatment Goal per ACC/AHA Guideline, 2014 Expert Panel Report, and JNC7 Based on the 2013 to 2016 PINNACLE Registry Data
| Characteristics | ACC/AHA guideline | 2014 Report | Difference between ACC/AHA guideline and 2014 report | JNC7 | Difference between ACC/AHA guideline and JNC7 |
|---|---|---|---|---|---|
| Total No. | 1 404 435 | 2 703 939 | 1 299 504 | 2 189 612 | 785 177 |
| Age, y | |||||
| Mean±SD | 67.7±13.7 | 67.6±13.4 | 67.4±13.0 | 67.0±13.7 | 68.5±13.8 |
| Median (Q1–Q3) | 69.0 (60.0–78.0) | 69.0 (60.0–77.0) | 69.0 (60.0–77.0) | 69.0 (58.0–77.0) | 67.0 (57.0–75.0) |
| Range (minimum–maximum) | 18.0–100.0 | 18.0–100.0 | 18.0–100.0 | 18.0–100.0 | 18.0–100.0 |
| 18–44 | 5.8 | 5.6 | 5.4 | 6.4 | 7.4 |
| 45–54 | 9.9 | 10.1 | 10.3 | 11.1 | 13.2 |
| 55–64 | 20.8 | 21.2 | 21.7 | 21.7 | 23.3 |
| 65–74 | 30.3 | 31.1 | 31.9 | 29.8 | 28.8 |
| ≥75 | 33.2 | 32.0 | 30.8 | 31.1 | 27.3 |
| Sex | |||||
| Men | 52.5 | 51.7 | 50.8 | 52.0 | 51.1 |
| Women | 47.5 | 48.3 | 49.2 | 48.0 | 48.9 |
| Race | |||||
| White | 64.8 | 64.3 | 63.7 | 64.6 | 64.1 |
| Black | 5.4 | 6.3 | 7.2 | 5.9 | 6.7 |
| Other * | 0.5 | 0.5 | 0.5 | 0.5 | 0.4 |
| Missing | 29.2 | 29.0 | 28.6 | 29.1 | 28.8 |
| History of stroke/TIA | 12.7 | 12.5 | 12.2 | 12.1 | 11.1 |
| History of stroke | 9.8 | 9.6 | 9.4 | 9.4 | 8.6 |
| History of TIA | 4.0 | 3.9 | 3.9 | 3.8 | 3.4 |
| Coronary artery disease | 49.1 | 46.4 | 43.4 | 46.1 | 40.7 |
| History of MI | 13.2 | 11.8 | 10.3 | 12.1 | 10.3 |
| History of PCI | 17.5 | 16.3 | 15.0 | 16.2 | 14.0 |
| History of CABG | 9.3 | 8.4 | 7.4 | 8.2 | 6.3 |
| Diabetes | 23.9 | 21.6 | 19.1 | 15.3 | 0.0 |
| Chronic kidney disease | 4.7 | 4.0 | 3.3 | 3.0 | 0.0 |
| Heart failure | 21.5 | 18.9 | 16.0 | 19.2 | 14.9 |
| 10‐y Predicted ASCVD risk, % | |||||
| Mean±SD (N) | 13.3±10.8 (18 590) | 14.6±11.4 (40 092) | 15.6±11.7 (21 502) | 12.7±10.1 (32 192) | 11.9±9.1 (13 602) |
| Median (Q1–Q3) | 10.6 (4.9–19.1) | 11.8 (5.6–20.9) | 12.8 (6.4–22.4) | 10.1 (4.8–18,3) | 9.4 (4.7–17.1) |
| Range (minimum–maximum) | 0.1–80.7 | 0.1–80.7 | 0.1–72.2 | 0.1–80.7 | 0.1–63.1 |
| <5 | 25.5 | 22.1 | 19.1 | 26.2 | 27.1 |
| 5–<10 | 22.3 | 21.6 | 21.0 | 23.6 | 25.4 |
| 10–<20 | 29.0 | 29.4 | 29.7 | 28.8 | 28.6 |
| ≥20 | 23.2 | 26.9 | 30.2 | 21.4 | 18.9 |
| History of CVD | 60.1 | 57.0 | 53.7 | 56.8 | 51.0 |
Proportions and 95% Clopper‐Pearson (exact) CIs were reported. ACC indicates American College of Cardiology; AHA, American Heart Association; ASCVD, atherosclerotic CVD; BP, blood pressure; CABG, coronary artery bypass grafting; CVD, cardiovascular disease; JNC7, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; MI, myocardial infarction; PCI, percutaneous coronary intervention; PINNACLE, Practice Innovation and Clinical Excellence; Q1, quartile 1; Q3, quartile 3; and TIA, transient ischemic attack.
*Defined as combination of any race other than White or Black, including Asian, American Indian/Alaskan Native, Native Hawaiin/ Pacific Islander.